roche glp-1 ADA '26: Lilly's dominance, Pfizer's 'foundational' drug and Roche's 'me-too' option Roche's GLP1/GIP drug sees 22.5%

Branded partnerships, alternative weight-loss therapies, and expansion in core categories can offset some pressure, but investors will demand clearer evidence of durable unit economics without regulatory gray zones driving acquisition

doi:10.2147/CCID.S68424 Lorestani S, Bahari A, Asadi M, Zahedi Avval F

Sexual dimorphism in selenium metabolism and selenoproteins

Algorithm for thyroid hormone replacement in adults with subclinical hypothyroidism due to Hashimotos thyroiditis 9 *Patients who commence LT4 therapy for symptoms attributed to subclinical hypothyroidism should be reviewed after three or four months to assess response to treatment once the serum TSH returns to the reference range

Origin: Made in South Korea